MarketCap
Facebook
X
Telegram
Acorda Therapeutics Balance Sheet 2023-2007 | ACOR
Brief overview of Acorda Therapeutics's balance sheet strength
The review uses the five latest available annual reports between 2016 and 2020.
Assets finished at $632.7 million versus $1.3 billion initially, losing -52.9%. The balance sheet contracted.
Funding shifted toward liabilities: they gained -41.8%, compared with -52.9% for assets.
Equity represents 37.6% of assets versus 49.5% initially. The capital structure appears balanced.
Net debt is $74.2 million, or 0.31x of equity. This is a conservative debt position.
The cash reserve occupies 11.3% of the balance sheet, previously 11.8%. It is one marker of short-term resilience.
The balance sheet includes a negative accumulated result of -$766.4 million. It should be assessed alongside historical profits and capital distributions.
Balance sheet takeaway
Acorda Therapeutics's balance sheet profile remains vulnerable. Lower liabilities and capital accumulation are the main routes to improvement.
Annual Balance Sheet Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | 131 M | 114 M | 74.2 M | 138 M | 25.1 M | 1.74 M | 141 M | 137 M | 106 M | -46.7 M | -39.6 M | -55.1 M | -29.8 M | -35.5 M | - | - |
Long Term Debt |
- | 167 M | 151 M | 138 M | 193 M | 319 M | 309 M | 299 M | 290 M | 288 M | 493 K | 1.11 M | 1.9 M | 3.59 M | 5.63 M | - | - |
Long Term Debt Current |
1.59 M | 1.54 M | 8.19 M | 7.94 M | 7.75 M | - | - | - | 25 K | 893 K | 861 K | 1.13 M | 1 M | 1.3 M | 6.18 M | - | - |
Total Non Current Liabilities |
- | - | - | 257 M | 403 M | 547 M | 534 M | 530 M | 423 M | 426 M | 70.1 M | 80.5 M | 86.9 M | - | - | - | - |
Total Current Liabilities |
228 M | 38 M | 54 M | 137 M | 86.4 M | 140 M | 144 M | 148 M | 90.6 M | 114 M | 96.6 M | 98.9 M | 87.3 M | 93.9 M | 72.9 M | - | - |
Total Liabilities |
- | - | - | 395 M | 489 M | 688 M | 678 M | 678 M | 513 M | 540 M | 167 M | 179 M | 174 M | - | - | - | - |
Deferred Revenue |
227 K | 384 K | - | - | - | - | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 38.3 M | 9.06 M | 9.43 M | 9.43 M | - | - |
Retained Earnings |
-1.19 B | -936 M | -870 M | -766 M | -667 M | -394 M | -455 M | -244 M | -209 M | -220 M | -238 M | -255 M | -409 M | -440 M | -428 M | - | - |
Total Assets |
109 M | 396 M | 455 M | 633 M | 800 M | 1.3 B | 1.2 B | 1.34 B | 1.11 B | 1.07 B | 607 M | 565 M | 379 M | 342 M | 319 M | - | - |
Cash and Cash Equivalents |
30 M | 37.5 M | 45.6 M | 71.4 M | 62.1 M | 294 M | 307 M | 159 M | 153 M | 182 M | 48 M | 41.9 M | 58 M | 34.6 M | 47.3 M | 29.6 M | 16.8 M |
Book Value |
109 M | 396 M | 455 M | 238 M | 311 M | 612 M | 520 M | 664 M | 598 M | 525 M | 440 M | 386 M | 205 M | 342 M | 319 M | - | - |
Total Shareholders Equity |
-158 M | 93.6 M | 151 M | 238 M | 311 M | 612 M | 520 M | 664 M | 603 M | 540 M | 440 M | 386 M | 205 M | 151 M | 137 M | 207 M | 63.4 M |
All numbers in USD currency
Quarterly Balance Sheet Acorda Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.85 M | 181 M | 176 M | 171 M | 167 M | 163 M | 159 M | 155 M | 151 M | 147 M | 144 M | 141 M | 138 M | 135 M | 132 M | 195 M | 193 M | 326 M | 324 M | 321 M | 319 M | 316 M | 314 M | 311 M | 309 M | 306 M | 304 M | 302 M | 299 M | 297 M | 295 M | 293 M | 290 M | 293 M | 292 M | 290 M | 288 M | 14 K | 258 K | 344 K | 493 K | 659 K | 753 K | 891 K | 1.11 M | 1.25 M | 1.54 M | 1.91 M | 1.9 M | 2.62 M | 2.99 M | 3.33 M | 4.37 M | 4.98 M |
Deferred Revenue |
294 K | 465 K | 548 K | 384 K | 384 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | - | - | - | - | - | - | - | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 9.43 M | 9.43 M |
Retained Earnings |
-1.22 B | -971 M | -962 M | -953 M | -936 M | -955 M | -942 M | -895 M | -870 M | -850 M | -823 M | -800 M | -766 M | -683 M | -691 M | -673 M | -667 M | -732 M | -469 M | -441 M | -394 M | -403 M | -390 M | -436 M | -455 M | -284 M | -259 M | -251 M | -244 M | -241 M | -228 M | -210 M | -209 M | -219 M | -222 M | -223 M | -220 M | -221 M | -233 M | -237 M | -238 M | -244 M | -252 M | -256 M | -255 M | -387 M | -397 M | -402 M | -409 M | -422 M | -441 M | -441 M | -444 M | -456 M |
Total Assets |
81.6 M | 366 M | 365 M | 375 M | 396 M | 393 M | 406 M | 424 M | 455 M | 466 M | 491 M | 584 M | 633 M | 710 M | 728 M | 754 M | 800 M | 880 M | 1.2 B | 1.23 B | 1.3 B | 1.31 B | 1.25 B | 1.19 B | 1.2 B | 1.35 B | 1.33 B | 1.32 B | 1.34 B | 1.32 B | 1.35 B | 1.21 B | 1.11 B | 1.1 B | 1.1 B | 1.1 B | 1.07 B | 973 M | 943 M | 612 M | 607 M | 587 M | 576 M | 565 M | 565 M | 410 M | 403 M | 386 M | 379 M | 351 M | 336 M | 336 M | 331 M | 296 M |
Cash and Cash Equivalents |
9.36 M | 32.5 M | 25.3 M | 30.3 M | 37.5 M | 20.7 M | 23.1 M | 31.9 M | 45.6 M | 36.2 M | 45.7 M | 117 M | 71.4 M | 57.9 M | 40.6 M | 32.4 M | 62.1 M | 120 M | 148 M | 197 M | 294 M | 321 M | 243 M | 226 M | 307 M | 192 M | 141 M | 134 M | 159 M | 128 M | 137 M | 431 M | 153 M | 89.8 M | 76.2 M | 61.5 M | 182 M | 53.3 M | 275 M | 44.4 M | 48 M | 46.3 M | 42.7 M | 34.7 M | 41.9 M | 40 M | 64.7 M | 55.3 M | 58 M | 44.4 M | 48.6 M | 78.5 M | 82.4 M | 75.7 M |
Book Value |
81.6 M | 366 M | 365 M | 375 M | 396 M | 393 M | 406 M | 424 M | 455 M | 466 M | 491 M | 584 M | 633 M | 710 M | 728 M | 754 M | 800 M | 880 M | 1.2 B | 1.23 B | 1.3 B | 1.31 B | 1.25 B | 1.19 B | 1.2 B | 1.35 B | 1.33 B | 1.32 B | 1.34 B | 1.32 B | 1.35 B | 1.21 B | 1.11 B | 1.1 B | 1.1 B | 1.1 B | 1.07 B | 973 M | 943 M | 612 M | 607 M | 587 M | 576 M | 565 M | 565 M | 410 M | 403 M | 386 M | 379 M | 351 M | 336 M | 336 M | 331 M | 296 M |
Total Shareholders Equity |
-186 M | 59 M | 67.9 M | 77 M | 93.6 M | 75.8 M | 87.9 M | 128 M | 151 M | 164 M | 190 M | 206 M | 238 M | 314 M | 291 M | 307 M | 311 M | 281 M | 545 M | 567 M | 612 M | 599 M | 607 M | 550 M | 520 M | 680 M | 690 M | 676 M | 664 M | 667 M | 672 M | 684 M | 603 M | 575 M | 560 M | 549 M | 540 M | 523 M | 500 M | 451 M | 440 M | 426 M | 405 M | 392 M | 386 M | 245 M | 230 M | 219 M | 205 M | 187 M | 163 M | 155 M | 142 M | 123 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Acorda Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
France
Israel
Germany
Britain
Russia
Belgium
